Press release

Insmed to Present at the Cowen and Company 40th Annual Health Care Conference

BRIDGEWATER, N.J., Feb. 26, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of

articleInsmed IncorporatedFebruary 26, 20204/company/insmed-inc/news/insmed-to-present-at-the-cowen-and-company-40th-annual-health-care-conference-2020-02
Insmed to Present at the Cowen and Company 40th Annual Health Care Conference

About this update from Insmed Incorporated

[{"type":"text","content":"BRIDGEWATER, N.J., Feb. 26, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that Will Lewis, Chairman and Chief Executive Officer of Insmed, will present at the Cowen and Company 40th Annual Health Care Conference in Boston on Tuesday, March 3, 2020, at 9:20 a.m. ET.\nThe presentation will be webcast live and can be accessed by visiting the investor relations section of the company's website at www.insmed.com. The webcast will be archived for a period of 30 days following the conclusion of the live event.\nAbout Insmed\nInsmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension. For more information, visit www.insmed.com.\nContact:\nInvestors:\nArgot PartnersLaura Perry or Heather Savelle(212) [email protected]\nMedia:\nMandy FaheySenior Director, Corporate CommunicationsInsmed (732) [email protected] \n\n \n\n\n\n View original content to download multimedia:http://www.prnewswire.com/news-releases/insmed-to-present-at-the-cowen-and-company-40th-annual-health-care-conference-301008803.html\nSOURCE Insmed Incorporated","length":4269,"tagName":"div"}]

More updates from Insmed Incorporated